Inhibikase Therapeutics, Inc.
IKT evidence brief
What we can confirm
- BioSniper Score:
- 7.0 / 10
- Market Cap:
- $325.1M
- Next Catalyst:
- Phase3_Start · Oct 23, 2026
What it means
What to watch
Prepared research question
What matters most for IKT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · IKT
Inhibikase Therapeutics is a clinical-stage biopharmaceutical company developing IKT-001, a prodrug of imatinib mesylate, for Pulmonary Arterial Hypertension (PAH), currently in Phase 3 trials.
Key risk: No product revenue
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Tracking 4 clinical trials · 1 catalyst for Inhibikase Therapeutics, Inc..
Inhibikase Therapeutics is a clinical-stage biopharmaceutical company developing IKT-001, a prodrug of imatinib mesylate, for Pulmonary Arterial Hypertension (PAH), currently in Phase 3 trials.
- Inhibikase Therapeutics is a clinical-stage company focused on IKT-001, a novel once-daily oral anti-proliferative for PAH [news · published 2026-08-11].
- IKT-001 is a prodrug of imatinib mesylate, an inhibitor of Abelson Tyrosine Kinase and type III receptor tyrosine kinases [pipeline].
- The company reported total revenue of $0.0M and a net loss of -$19.6M for the period ending June 30, 2026 [latest reported financials].
- Shareholders' equity stood at $153.3M as of June 30, 2026 [latest reported financials].
- The FDA granted Orphan Drug Designation for IKT-001 for the treatment of PAH in July 2026 [news · published 2026-07-23].
What works
- IKT-001 has advanced to Phase 3 clinical trials (IMPROVE-PAH study) with 26 country regulatory approvals, indicating progress in the development pipeline [news · published 2026-08-11].
- The company has secured Orphan Drug Designation from the FDA for IKT-001, which may provide development and commercialization incentives [news · published 2026-07-23].
- Inhibikase has a collaboration with Pivot Holding LLC for commercialization rights to certain linkers, with a potential $4.4 million payment upon FDA approval [pipeline].
- Management believes existing cash and marketable securities as of June 30, 2026, plus capital raised in July 2026, can fund operations through topline data readout in Part B of the Phase 3 study [sec_mda · as of 2026-08-11].
What to weigh
- The company has no significant revenue from product sales and expects to continue incurring significant losses for the foreseeable future [sec_mda · as of 2026-08-11].
- Drug development is subject to numerous risks and uncertainties, including the ability to complete trials, obtain regulatory approval, and commercialize products [sec_mda · as of 2026-08-11].
- The company's cash runway estimates are based on assumptions that may prove incorrect, and working capital could be depleted sooner than expected [sec_mda · as of 2026-08-11].
- Inhibikase faces a competitive landscape in PAH, including large pharmaceutical companies such as GlaxoSmithKline, Johnson and Johnson, and Novartis [pipeline].
From the filings
Quoted directly from source documents.
IKT-001 is a prodrug of imatinib mesylate targeting PAH
“Pipeline Candidate: ikt-001 Generic Name: imatinib mesylate (prodrug) Indication: Pulmonary Arterial Hypertension”
Pipeline
FDA granted Orphan Drug Designation for IKT-001
“FDA Grants Orphan Drug Designation To Its Lead Product Candidate IKT-001, Prodrug Of Imatinib Mesylate, For Treatment Of PAH”
News · July 23, 2026
Management expects cash to fund operations through topline data readout
“will support operations through topline data readout in Part B of our ongoing global Phase 3 IMPROVE-PAH clinical study”
SEC MD&A · August 11, 2026
Catalyst timeline
- 2026-10-23 · Phase3_Start: Open-Label, Long-Term Extension Study to Evaluate the Safety and Tolerability of IKT-001 in Pulmonary Arterial Hypertension — Initiation of a long-term safety extension study for IKT-001 in PAH patients.
Risks & what to watch (4)›
Key risks
- No product revenue — Company has no significant revenue and expects continued losses until potential commercialization [sec_mda · as of 2026-08-11].
- Clinical and regulatory uncertainty — Drug development faces risks in trial completion, safety profile, and FDA approval [sec_mda · as of 2026-08-11].
- Cash runway assumptions — Funding estimates rely on assumptions that may be wrong; working capital could deplete sooner [sec_mda · as of 2026-08-11].
- Competitive PAH landscape — Multiple large pharmaceutical companies are active in PAH, increasing competitive pressure [pipeline].
What to watch
- Progress and topline data readout from the Phase 3 IMPROVE-PAH study (Part B) [sec_mda · as of 2026-08-11].
- Regulatory milestones, including potential NDA submission under 505(b)(2) pathway [pipeline].
- Cash position and any additional capital raises, especially related to warrant exercises [sec_mda · as of 2026-08-11].
- Competitive developments in PAH from other companies [pipeline].
Sources: Catalysts · News · Pipeline · SEC MD&A · Generated October 6, 2026 · How we verify sources →
Run Inhibikase Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Inhibikase Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
D/E 0.07 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
1 upcoming, next in ~9d
No insider transactions in the last 180 days
Catalysts
Regulatory
Financials
Short Interest
as of May 21, 2026- % of float
- 21.9%
- Days to cover
- 18.3
- Shares short
- 17,979,022
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
IKT short interestGovernance
Frequently asked questions
What is the AI investment thesis for Inhibikase Therapeutics, Inc.?
Inhibikase Therapeutics is a clinical-stage biopharmaceutical company developing IKT-001, a prodrug of imatinib mesylate, for Pulmonary Arterial Hypertension (PAH), currently in Phase 3 trials.
What is Inhibikase Therapeutics, Inc.'s next catalyst?
Inhibikase Therapeutics, Inc.'s next tracked catalyst is a Phase3_Start event — "Phase3_Start: Open-Label, Long-Term Extension Study to Evaluate the Safety and Tolerability of IKT-001 in Pulmonary Arterial Hypertension" — expected October 23, 2026.
Who is the CEO of Inhibikase Therapeutics, Inc.?
Mr. Mark T. Iwicki is the chief executive officer of Inhibikase Therapeutics, Inc. (IKT).
Where is Inhibikase Therapeutics, Inc. headquartered?
Inhibikase Therapeutics, Inc. (IKT) is headquartered in Wilmington, DE, United States.
What therapeutic areas does Inhibikase Therapeutics, Inc. focus on?
Inhibikase Therapeutics, Inc. develops therapies across Oncology, Neurology, Cardiovascular, Respiratory.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.